|
When alcoholism and drug addiction are discussed, the tone tends to
be sympathetic. When obesity is discussed, the conversation is dominated by
mockery and blame, though the evidence suggests that it can be driven by similar
forms of addiction (citations 1,2,3,4). I suspect that much of this mockery is a
coded form of snobbery: the strong association between poor diets and poverty
allows people to use this issue as a cipher for something else they want to say,
which is less socially acceptable.
But this problem belongs to all of us. Even if you can detach
yourself from the suffering caused by diseases arising from bad diets, you will
carry the cost, as a growing proportion of the health budget will be used to
address them. The cost – measured in both human suffering and money – could be
far greater than we imagined. A large body of evidence now suggests that
Alzheimer’s is primarily a metabolic disease. Some scientists have gone so far
as to rename it. They call it diabetes type 3.
New Scientist carried this story on its cover this
September(5): since then I’ve been sitting in the library trying to discover
whether it stands up. I’ve now read dozens of papers on the subject, testing my
cognitive powers to the limit as I’ve tried to get to grips with brain
chemistry. While the story is by no means complete, the evidence so far is
compelling.
Around 35 million people suffer from Alzheimer’s disease
worldwide(6); current projections, based on the rate at which the population
ages, suggest that this will rise to 100 million by 2050(7). But if, as many
scientists now believe, it is caused largely by the brain’s impaired response to
insulin, the numbers could rise much further. In the US, the percentage of the
population with diabetes type 2, which is strongly linked to obesity, has almost
trebled in 30 years(8). If Alzheimer’s, or “diabetes type 3”, goes the same way,
the potential for human suffering is incalculable.
Insulin is the hormone which prompts the liver, muscles and fat to
absorb sugar from the blood. Diabetes 2 is caused by excessive blood glucose,
resulting either from a deficiency of insulin produced by the pancreas, or
resistance to its signals by the organs which would usually take up the
glucose.
The association between Alzheimer’s and diabetes 2 is
long-established: type 2 sufferers are two to three times more likely to be
struck by this dementia than the general population(9). There are also
associations between Alzheimer’s and obesity(10) and Alzheimer’s and metabolic
syndrome (a complex of diet-related pathologies)(11).
Researchers first proposed that Alzheimer’s was another form of
diabetes in 2005. The authors of the original paper investigated the brains of
54 corpses, 28 of which belonged to people who had died of the disease(12). They
found that the levels of both insulin and insulin-like growth factors in the
brains of Alzheimer’s patients were sharply reduced by comparison to those in
the brains of people who had died of other causes. Levels were lowest in the
parts of the brain most affected by the disease.
Their work led them to conclude that insulin and insulin-like growth
factor are produced not only in the pancreas but also in the brain. Insulin in
the brain has a host of functions: as well as glucose metabolism, it helps to
regulate the transmission of signals from one nerve cell to another, and affects
their growth, plasticity and survival(13,14).
Experiments conducted since then appear to support the link between
diet and dementia(15,16,17,18), and researchers have begun to propose potential
mechanisms. In common with all brain chemistry, these tend to be fantastically
complex, involving, among other impacts, inflammation, stress caused by
oxidation, the accumulation of one kind of brain protein and the transformation
of another(19,20,21,22). I would need the next six pages of this paper even to
begin to explain them, and would doubtless get it wrong (if you’re interested,
please follow the links on my website).
Plenty of research still needs to be done. But if the current
indications are correct, Alzheimer’s disease could be another catastrophic
impact of the junk food industry, and the worst discovered so far. Our
governments, as they are in the face of all our major crises, appear to be
incapable of responding.
In this country as in many others, the government’s answer to the
multiple disasters caused by the consumption of too much sugar and fat is to
call on both companies and consumers to regulate themselves. Before he was
replaced by someone even worse, the former health secretary, Andrew Lansley,
handed much of the responsibility for improving the nation’s diet to food and
drinks companies: a strategy that would work only if they volunteered to abandon
much of their business(23,24).
A scarcely-regulated food industry can engineer its products –
loading them with fat, salt, sugar and high fructose corn syrup – to bypass the
neurological signals which would otherwise prompt people to stop eating(25).
It can bombard both adults and children with advertising. It can (as we
discovered yesterday) use the freedoms granted to academy schools to sell the
chocolate, sweets and fizzy drinks now banned from sale in maintained schools(26).
It can kill the only effective system (the traffic light label) for informing
people how much fat, sugar and salt their food contains. Then it can turn to the
government and blame consumers for eating the products it sells. This is class
war: a war against the poor fought by the executive class in government and
industry.
We cannot yet state unequivocally that poor diet is a leading cause
of Alzheimer’s disease, though we can say that the evidence is strong and
growing. But if ever there was a case for the precautionary principle, here it
is. It’s not as if we lose anything by eating less rubbish. Averting a possible
epidemic of this devastating disease means taking on the bullies: those who mock
people for their pathologies and those who spread the pathologies by peddling a
lethal diet.
References:
1. Caroline Davis et al, 2011. Evidence that ‘food addiction’ is a
valid phenotype of obesity. Appetite Vol. 57, pp711–717.
doi:10.1016/j.appet.2011.08.017
2. Paul J. Kenny, November 2011. Common cellular and molecular
mechanisms in obesity and drug addiction. Nature Neuroscience, Vol. 12, pp
638-651. doi:10.1038/nrn3105
3. Joseph Frascella et al, 2010. Shared brain vulnerabilities open
the way for nonsubstance addictions: Carving addiction
at a new joint? Annals of the New York Academy of Sciences, Vol. 1187, pp294–315.
doi: 10.1111/j.1749-6632.2009.05420.x
at a new joint? Annals of the New York Academy of Sciences, Vol. 1187, pp294–315.
doi: 10.1111/j.1749-6632.2009.05420.x
4. Ashley N. Gearhardt et al, 2010. Can food be addictive? Public
health and policy implications. Addiction, 106, 1208–1212. ad. d_3301
1208..1212
doi:10.1111/j.1360-0443.2010.03301.x
doi:10.1111/j.1360-0443.2010.03301.x
5. Bijal Trivedi, 1st September 2012. Eat Your Way to Dementia. New
Scientist.
6. Sónia C. Correia et al, 2011. Insulin-resistant brain state: The
culprit in sporadic Alzheimer’s disease? Ageing Research Reviews Vol. 10,
264–273. doi:10.1016/j.arr.2011.01.001
7. Fabio Copped`e et al, 2012. Nutrition and Dementia. Current
Gerontology and Geriatrics Research, Vol. 2012,
pp1-3.
doi:10.1155/2012/926082
doi:10.1155/2012/926082
8. See the graph in Bijal Trivedi, 1st September 2012. Eat Your Way
to Dementia. New Scientist.
9. Johanna Zemva and Markus Schubert, September 2011. Central
Insulin and Insulin-Like Growth Factor-1 Signaling – Implications for Diabetes
Associated Dementia. Current Diabetes Reviews, Vol.7, No.5, pp356-366.
doi.org/10.2174/157339911797415594
10. Eg Weili Xu et al, 2011. Midlife overweight and obesity increase
late life dementia risk: a population-based twin study. Neurology, Vol. 76, no.
18, pp.1568–1574.
11. M. Vanhanen et al, 2006. Association of metabolic syndrome with
Alzheimer disease: A population-based study. Neurology, vol. 67, pp.843–847.
12. Eric Steen et al, 2005. Impaired insulin and insulin-like growth
factor expression and signaling mechanisms in Alzheimer’s disease – is this type
3 diabetes?.
Journal of Alzheimer’s Disease, Vol. 7, pp.63–80.
Journal of Alzheimer’s Disease, Vol. 7, pp.63–80.
13. Konrad Talbot et al, 2012. Demonstrated brain insulin resistance
in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1
dysregulation, and cognitive decline. The Journal of Clinical Investigation,
Vol.122, No.4, pp.1316–1338. doi:10.1172/JCI59903.
14. Naoki Yamamoto et al, 2012. Brain insulin resistance accelerates
Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic
membranes. Journal of Neurochemistry, Vol. 121, 619–628. doi:
10.1111/j.1471-4159.2012.07668.x
15. Eg:
Wei-Qin Zhao and Matthew Townsend, 2009. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease.
Biochimica et Biophysica Acta, Vol.1792, pp.482–496. doi.org/10.1016/j.bbadis.2008.10.014,
Wei-Qin Zhao and Matthew Townsend, 2009. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease.
Biochimica et Biophysica Acta, Vol.1792, pp.482–496. doi.org/10.1016/j.bbadis.2008.10.014,
16. Sónia C. Correia et al, 2011. Insulin-resistant brain state: The
culprit in sporadic Alzheimer’s disease? Ageing Research Reviews Vol. 10,
264–273. doi:10.1016/j.arr.2011.01.001
17. T. Ohara et al, 2011. Glucose tolerance status and risk of
dementia in the community, the Hisayama study. Neurology, Vol. 77,
pp.1126–1134.
18. Karen Neumann et al, 2008. Insulin resistance and Alzheimer’s
disease: molecular links & clinical implications. Current Alzheimer
Research, Vol.5, no.5, pp438–447.
19. Eg: Lap Ho et al, 2012. Insulin Receptor Expression and Activity
in the Brains of
Nondiabetic Sporadic Alzheimer’s Disease Cases. International Journal of Alzheimer’s Disease, Volume 2012. doi:10.1155/2012/321280
Nondiabetic Sporadic Alzheimer’s Disease Cases. International Journal of Alzheimer’s Disease, Volume 2012. doi:10.1155/2012/321280
20. Suzanne M. de la Monte, 2012. Contributions of Brain Insulin
Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s
Disease. Drugs, Vol. 72, no.1, pp. 49-66. doi: 10.2165/11597760
21. Ying Liu et al, 2011. Deficient brain insulin signalling pathway
in Alzheimer’s disease and diabetes. Journal of Pathology, Vol. 225, pp.54–62.
doi: 0.1002/path.2912
22. Konrad Talbot et al, 2012. Demonstrated brain insulin resistance
in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1
dysregulation, and cognitive decline. The Journal of Clinical Investigation,
Vol.122, No.4, pp.1316–1338. doi:10.1172/JCI59903.
No comments:
Post a Comment